Bain Capital Life Sciences Investors’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.59M | Hold |
1,111,910
| – | – | 0.2% | 20 |
|
|
2025
Q1 | $1.78M | Hold |
1,111,910
| – | – | 0.26% | 21 |
|
|
2024
Q4 | $4M | Hold |
1,111,910
| – | – | 0.47% | 21 |
|
|
2024
Q3 | $6.34M | Hold |
1,111,910
| – | – | 0.66% | 18 |
|
|
2024
Q2 | $5.14M | Sell |
1,111,910
-30,300
| -3% | -$140K | 0.56% | 19 |
|
|
2024
Q1 | $9.33M | Sell |
1,142,210
-500,000
| -30% | -$4.09M | 0.75% | 20 |
|
|
2023
Q4 | $9.28M | Hold |
1,642,210
| – | – | 0.89% | 19 |
|
|
2023
Q3 | $3.05M | Hold |
1,642,210
| – | – | 0.34% | 29 |
|
|
2023
Q2 | $4.52M | Hold |
1,642,210
| – | – | 0.47% | 28 |
|
|
2023
Q1 | $5.16M | Hold |
1,642,210
| – | – | 0.64% | 29 |
|
|
2022
Q4 | $9.69M | Hold |
1,642,210
| – | – | 1.08% | 23 |
|
|
2022
Q3 | $14.4M | Hold |
1,642,210
| – | – | 1.72% | 18 |
|
|
2022
Q2 | $12.4M | Hold |
1,642,210
| – | – | 1.45% | 17 |
|
|
2022
Q1 | $39.8M | Hold |
1,642,210
| – | – | 3.87% | 9 |
|
|
2021
Q4 | $52.9M | Buy |
1,642,210
+1
| +0% | +$32 | 4.19% | 8 |
|
|
2021
Q3 | $73.4M | Hold |
1,642,209
| – | – | 4.55% | 8 |
|
|
2021
Q2 | $62.1M | Hold |
1,642,209
| – | – | 4.07% | 7 |
|
|
2021
Q1 | $60.7M | Hold |
1,642,209
| – | – | 3.44% | 8 |
|
|
2020
Q4 | $54.4M | Buy |
+1,642,209
| New | +$54.4M | 3.42% | 8 |
|